# Natasha B. Leighl

Source: https://onco.cc/people/natasha-leighl/  
OnCo record `natasha-leighl` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Lung cancer oncologist who showed plasma genotyping matches tissue and leads Canadian lung trials.

## Summary

Natasha B. Leighl is Lung Site Lead in Medical Oncology and holds the OSI Pharmaceuticals Foundation Chair in Cancer New Drug Development at the Princess Margaret Cancer Centre. She is a lung cancer oncologist known for leading the NILE study, which showed that plasma cell-free DNA genotyping matches tissue testing in non-small-cell lung cancer, and for leading numerous Canadian Cancer Trials Group lung studies. Her selected paper reports the clinical utility of comprehensive cell-free DNA analysis in newly diagnosed metastatic lung cancer. A past president of the IASLC, she continues to work on liquid biopsy and health economics.

## Fields

- Kind: Person
- Last checked: 2026-09-08
- Role: Lung Site Lead, Medical Oncology; OSI Pharmaceuticals Foundation Chair in Cancer New Drug Development
- Specialisms: Lung cancer; Liquid biopsy; Health economics

## Sources

- UHN profile: https://www.uhnresearch.ca/researcher/natasha-b-leighl
- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Leighl%20NB%5BAuthor%5D

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- technologies: [Liquid biopsy (ctDNA)](https://onco.cc/technologies/liquid-biopsy/)
- institutions: [Princess Margaret Cancer Centre](https://onco.cc/institutions/princess-margaret/)

---
JSON: https://onco.cc/api/v1/entities/natasha-leighl.json